Management of Paget's disease of bone: reply
We thank Drs Jawad and Crisp for their interest in our review [1] and read their comments with interest.
With regard to the terminology for Paget's disease of bone/ osteitis deformans/osteodystrophia deformans, we think that 'Paget's disease of bone' is as good a name as any, and we use this in preference to others as it is easily understood by health-care professionals and patients alike. We also suggest that when searching Medline for articles, it is useful to use both osteitis deformans and osteodystrophia deformans as search terms. Indeed, we'd recommend also using 'ostitis deformans' as it appears that there are many articles that have used this alternative spelling of Sir James Paget's original name for the disease.
We welcome Dr Crisp's comments on the use of pamidronate for the treatment of Paget's disease. The regimen outlined in our paper is that recommended by the manufacturer and outlined in the summary product characteristics for pamidronate as licensed within the UK. We recognize, however, that many other dose regimens of pamidronate have been successfully used in the treatment of Paget's disease and that as far as one can gather, these appear to be equally effective at suppressing serum alkaline phosphatase values [2] [3] [4] [5] [6] . There is no evidence to support the view that one regimen of pamidronate is better than another in terms of clinical response (or cost-effectiveness) since they have never been compared with each other in the context of a randomized controlled trial where clinical response and health economic issues have been addressed. This is relevant to the main point that we wanted to get across in our review, which is that there is little evidence to guide clinicians upon what the most appropriate management strategy is for any antiresorptive agent in Paget's disease. This is particularly true with regard to the prevention and treatment of complications of the disease such as fracture, pain, deafness and bone deformity. Hopefully, on-going studies such as the PRISM trial (http://www.abdn.ac.uk/hsru/hta/prism.shtml) will help to answer these questions and contribute to the development of future guidelines that will address the issues of efficient use of NHS time and resources mentioned by Dr Crisp. 
